单株抗体生物相似药市场规模、份额和成长分析：按产品类型、治疗领域、应用、最终用户、分销管道和地区划分 - 2026-2033 年行业预测

2024年全球单株抗体生物相似药市值为6.895亿美元，预计将从2025年的7.4259亿美元成长到2033年的13.4424亿美元。预测期（2026-2033年）的复合年增长率预计为7.7%。

由于原料药专利到期以及对经济高效、临床疗效相当的治疗方法的需求不断增长，全球单株抗体（mAb）生物相似药市场正经历显着增长。这些产品几乎是复杂蛋白质药物的复製品，对于肿瘤、免疫和罕见疾病的治疗至关重要，因为单株抗体是价格最昂贵的药物之一。监管政策的明确和可扩展生产方法的出现正在促进市场准入，推动价格下降并提高患者的用药可及性。生物相似药竞标的成功案例表明，竞争加剧，这促使临床医生转向更经济实惠的治疗方案。此外，人工智慧在研发阶段的应用，透过优化设计、提高可预测性和缩短研发週期，提高了效率，最终加快了市场准入速度，并促进了该领域的永续全球成长。

全球单株抗体生物相似药市场的驱动因素

全球单株抗体生物相似药市场的成长主要得益于旨在缓解患者面临的经济和后勤挑战的扩大患者准入计划的实施。透过提供共同支付支援、医疗系统导航以及患者和处方医生的教育，製造商正在提高这些治疗方法的可及性，惠及更广泛的患者群体。这些措施有助于建立医疗服务提供者之间的信任，促进治疗的连续性，并最终实现生物相似药的替代和重复处方。此外，透过製造商、医疗服务提供者和保险公司之间的合作优化准入途径，将进一步加速市场渗透，并培养对单株抗体生物相似药的持续需求。

全球单株抗体生物相似药市场的限制因素

全球单株抗体生物相似药市场面临源自复杂生产流程的诸多限制因素。这种复杂性造成了技术和营运壁垒，增加了研发难度和生产风险，阻碍了市场成长。对细胞株、纯化方法和品质标准的严格控制需要专业知识和对先进设施的大量投资。生产过程中的差异性进一步增加了监管机构对可比较性的评估难度，使得高效率的生产规模化难以实现。这阻碍了新进入者，并限制了产能扩张。对供应稳定性和产品品质的担忧限制了产品的普及，导致支付方和供应商在采购决策上更加谨慎。

全球单株抗体生物相似药市场趋势

全球单株抗体生物相似药市场正经历显着成长，新兴市场的扩张为其提供了强劲的发展机会。这些新兴市场医疗基础设施的改善和监管政策的进步，为市场创造了巨大的发展空间。製造商积极推动在地化伙伴关係，并采用个人化定价策略，以改善生物相似药的可及性，以应对不同的报销情况。此外，有针对性的分销策略以及与区域相关人员的合作，正在丰富产品系列，增强市场竞争力。为确保可持续的市场渗透，各公司正在实施符合当地文化的医护人员和患者互动策略，并根据各地区不断变化的医疗保健重点进行调整，最终推动全球生物相似药市场的需求和成长。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球单株抗体生物相似药市场规模：按产品类型和复合年增长率划分（2026-2033 年）

• Bevacizumab生物类似药
• Rituximab生物相似药
• 曲妥珠单抗生物相似药
• 其他单株抗体生物相似药

全球单株抗体生物相似药市场规模：按治疗领域和复合年增长率划分（2026-2033 年）

• 肿瘤学
• 自体免疫疾病
• 感染疾病
• 呼吸系统疾病
• 其他治疗领域

全球单株抗体生物相似药市场规模：依应用及复合年增长率划分（2026-2033 年）

• 医院药房
• 零售药房
• 专科诊所
• 契约製造组织

全球单株抗体生物相似药市场规模：按最终用户和复合年增长率划分（2026-2033 年）

• 医院
• 诊断中心
• 研究机构
• 生物技术和製药公司
• 其他的

全球单株抗体生物相似药市场规模：按分销管道和复合年增长率划分（2026-2033 年）

• 直销
• 批发商
• 网路药房

全球单株抗体生物相似药市场规模及复合年增长率（2026-2033）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• Amgen
• AbbVie
• Sandoz
• Teva Pharmaceuticals
• Mylan
• Pfizer
• Samsung Bioepis
• Biocon
• Fresenius Kabi
• Celltrion
• GSK
• Boehringer Ingelheim
• Johnson & Johnson
• Intas Pharmaceuticals
• EMD Serono
• Coherus Biosciences
• Apotex
• Novartis
• Merck
• Sun Pharmaceutical Industries

结论与建议

Global Mab Biosimilar Market size was valued at USD 689.5 Million in 2024 and is poised to grow from USD 742.59 Million in 2025 to USD 1344.24 Million by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).

The global monoclonal antibody (mAb) biosimilar market is witnessing significant growth due to the expiration of original biologic patents and increasing demand for cost-effective, clinically equivalent therapies. These near-identical copies of complex protein drugs are crucial for treating oncology, immunology, and rare diseases, as monoclonal antibodies are among the most expensive medications. As regulatory clarity and scalable manufacturing methods emerge, market entry has become easier, driving price reductions and broader patient access. Increased competition, exemplified by successful biosimilar tender processes, encourages clinicians to switch to more affordable options. Additionally, the integration of artificial intelligence in development enhances efficiency by optimizing design, improving predictability, and accelerating timelines, ultimately enabling faster market entry and sustainable global growth in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mab Biosimilar market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Mab Biosimilar Market Segments Analysis

Global mab biosimilar market is segmented by product type, therapeutic area, application, end-user, distribution channel and region. Based on product type, the market is segmented into Bevacizumab Biosimilars, Rituximab Biosimilars, Trastuzumab Biosimilars and Other Monoclonal Antibody Biosimilars. Based on therapeutic area, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases and Other Therapeutic Areas. Based on application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Clinics and Contract Manufacturing Organizations. Based on end-user, the market is segmented into Hospitals, Diagnostic Centers, Research Institutes, Biotechnology & Pharmaceutical Companies and Others. Based on distribution channel, the market is segmented into Direct Sales, Distributors and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Mab Biosimilar Market

The growth of the global mAb biosimilar market is significantly driven by the implementation of expanding patient access programs that aim to alleviate financial and logistical challenges faced by patients. By providing support for co-payments, navigating healthcare systems, and educating both patients and prescribers, manufacturers enhance the accessibility of these therapies to a wider audience. Such initiatives build trust among healthcare providers and facilitate continuity of care, ultimately promoting the substitution and repeated prescription of biosimilars. Additionally, collaboration between manufacturers, providers, and payers to optimize access pathways further boosts market penetration and fosters sustained demand for mAb biosimilars.

Restraints in the Global Mab Biosimilar Market

The global market for monoclonal antibody biosimilars faces significant restraints due to the intricate manufacturing processes involved. These complexities create technical and operational hurdles that hinder market growth, as they increase both development difficulties and production risks. The requirement for meticulous management of cell lines, purification methods, and quality standards necessitates specialized knowledge and substantial investment in advanced facilities. Variability in manufacturing can further complicate regulatory assessments of comparability, making it challenging to scale production effectively, which discourages new market entrants and impedes capacity growth. Concerns surrounding supply consistency and product quality lead to cautious procurement choices by payers and providers, limiting widespread adoption.

Market Trends of the Global Mab Biosimilar Market

The global mAb biosimilar market is experiencing significant growth, driven by the expansion of emerging markets where healthcare infrastructure improvement and regulatory advancements are creating robust opportunities. Manufacturers are actively forming local partnerships and adopting tailored pricing strategies to address varying reimbursement scenarios, enhancing access to biosimilars. Additionally, targeted distribution strategies and collaborative efforts with regional stakeholders facilitate portfolio diversification and strengthen competitive positioning. To ensure sustained market uptake, companies are implementing culturally relevant clinician and patient engagement initiatives that align with the evolving healthcare priorities of these regions, ultimately driving demand and growth in the global biosimilar landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Mab Biosimilar Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Bevacizumab Biosimilars
• Rituximab Biosimilars
• Trastuzumab Biosimilars
• Other Monoclonal Antibody Biosimilars

Global Mab Biosimilar Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Respiratory Diseases
• Other Therapeutic Areas

Global Mab Biosimilar Market Size by Application & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Clinics
• Contract Manufacturing Organizations

Global Mab Biosimilar Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutes
• Biotechnology & Pharmaceutical Companies
• Others

Global Mab Biosimilar Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Distributors
• Online Pharmacies

Global Mab Biosimilar Market Size & CAGR (2026-2033)

• North America (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Serono
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations